What our clients say
It has been a pleasure working with Lightning API – they are responsive, reliable, comprehensive, and thorough in their work. That’s what you’re looking for from a consultant, and that’s why we have been working on several projects already with them now.
Vice President, Business Development
Global pharmaceutical company
Having worked with several firms in this area and being on the other side myself, I have to say that the team at Lightning API really raises the standards bar. They have helped me on several different projects, always with a very pragmatic approach and delivering fantastic results. I can’t recommend this firm highly enough.
Senior Market Access Manager
Global pharmaceutical company
Beyond the market research I was really impressed by the true consultancy provided throughout the process, leading to strong evidence-based recommendations. Lightning API's ability to combine knowledge and experience with experts’ feedback and expertise is definitely strong added value compared to other research companies.
General Manager
Global pharmaceutical company
I worked with Lightning API on a key flagship program. Where other parties talked in broad assumptions, this, ...was highly innovative and creative. The team at Lightning API are true subject matter experts, and a lot of fun.
Global Business Development Lead
Large multinational medical device company
The team at Lightning API are quick, efficient and responsive. They gave us some important payer insights for our opioid induced constipation product. Based on these payer insights the team at Lightning API developed a suite of materials, including a value narrative and budget impact model, that forms the platform for our entire payer interactions.
Global Market Access Lead
Medium-sized pharmaceutical company
The Lightning API team was able to bring their considerable insight and experience into the project, delivering an in-depth analysis of the P&R systems across Europe, tailoring the findings to the therapy area of interest. The resulting playbook will be a valuable resource within the Company...for use with different assets and indications to help with strategic decision-making.
Associate Director, Market Access
British multinational pharmaceutical company
Lightning API in numbers
Lightning API
>600
members
of the payer network in the EU5 and US alone
>30
Markets
have formed the scope of our most recent research
>20,000
responses
have been made on the API platform in the last 6 months
News
Virtual cohorts: a method to overcome challenges in developing evidence in rare and complex diseases?
Eleanor Butler,  Consultant at Lightning API reviews the use of synthetic data and virtual cohorts to mitigate challenges associated with developing evidence in rare and complex diseases
Guidance for new Marketing Authorisation assessment routes in the UK following Brexit: International routes
In the last of our series of posts analysing the new access routes developed in the UK, Nasos Kipentzoglou, Analyst at Lightning API takes an in-depth look at the international routes; the Access Consortium and Project Orbis
Guidance for new Marketing Authorisation assessment routes in the UK following Brexit: Unfettered Access Procedure for marketing authorisations approved in Northern Ireland
In the penultimate of our series of posts analysing the new access routes developed in the UK, Nasos Kipentzoglou, Analyst at Lightning API takes a deeper dive into the Unfettered Access Procedure for marketing authorisations approved in Northern Ireland
Cancard launch marks an important step to improve attitudes towards medicinal cannabis and help reduce fear for those carrying cannabis-based products for medicinal reasons
Following the launch of Cancard in the UK, Nancy Cross, Analyst at Lightning API talks about the positive impact the launch may have on individuals carrying medicinal cannabis
Guidance for new Marketing Authorisation assessment routes in the UK following Brexit: Decentralised and Mutual Recognition Reliance Procedure
In the fourth of our series of posts analysing the new access routes developed in the UK, Nasos Kipentzoglou takes a deeper dive into at the Decentralised and Mutual Recognition Reliance Procedure
Guidance for new Marketing Authorisation assessment routes in the UK following Brexit: European Commission Decision reliance procedure
In the third of our series of posts analysing the new access routes developed in the UK, Nasos Kipentzoglou, Analyst at Lightning API looks at the European Commission Decision reliance procedure
Managing the symptoms of Parkinson’s Disease with medical cannabis: Exploring the patient perspective
Nancy Cross, Analyst at Lightning API takes a look at the power of the patient perspective and its importance in increasing the understanding of the potential benefits of medical cannabis
Guidance for new Marketing Authorisation assessment routes in the UK following Brexit: rolling review procedure
In the second of our series of posts analysing the new access routes developed in the UK, Nasos Kipentzoglou, Analyst at Lightning API takes a deeper dive into the rolling review procedure
ATMP Market Access: ensuring sustainable patient access to life-changing therapies
How Lightning API can support you to navigate your access challenges associated with ATMPs
Guidance for new Marketing Authorisation assessment routes in the UK following Brexit: 150-day National Procedure
In the first of a series of articles looking at the mechanisms to obtain marketing authorisation in the UK, Nasos Kipentzoglou, Analyst at Lightning API takes an in-depth look at the 150-day National Procedure and the possible implications for manufacturers
Retrospective analysis of NICE CAR-T therapy single technology appraisals and identification of strategies to minimise time to patient access
In this article, our colleagues Eleanor Butler and Nancy Cross carry out a retrospective review of the NICE CAR-T therapy single technology appraisals
Guidance for new Marketing Authorisation assessment routes in the UK following Brexit
In the intro of a series of articles, Nasos Kipentzoglou, Analyst at Lightning API provides a round up of the current mechanisms to obtain marketing authorisation in the UK
The G-BA implements post launch real world evidence generation for Zolgensma®
Nasos Kipentzoglou, Analyst at Lightning API reviews the recent approach that the G-BA has taken in requiring the mandatory collection of real world evidence for Zolgensma
NICE rejects gene therapy Zynteglo
Following NICE draft guidance rejecting Zynteglo, Eleanor Butler, Consultant at Lightning API explores why the beta thalassaemia treatment is not recommend for routine NHS funding
Implications of the UK Rare Diseases Framework for rare disease patients and manufacturers developing new treatments
Nancy Cross, Analyst, and Eleanor Butler, Consultant at Lightning API review the recently published framework and discuss what this means for stakeholders
Luxturna: reimbursement through the Italian fund for innovative oncology medicines
Eleanor Butler, Consultant and Joshua Beddow, Junior Analyst at Lightning API review the recent reimbursement of Luxturna in Italy